0.1900USD-35.59%Mkt Cap: —P/E: —Last update: 2026-06-01
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United Sta…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)5.66M USD
Gross Profit1.88M USD
Net Income (TTM)-14.91M USD
Revenue/Share2.089 USD
Last Price0.1900 USD
Fiscal Year End—
MR Quarter—
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.25
EPS (TTM)—
EPS (Forward)—
52W Range
0.125138% of range0.2950
52W High0.2950 USD
52W Low0.1251 USD
Profitability
Gross Margin30.80%
Oper. Margin-267.62%
EBITDA Margin-194.17%
Profit Margin-244.10%
ROE-204.87%
ROA-136.03%
Growth
Revenue Growth-27.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.33M USD
CapEx (TTM)60.57K USD
FCF Margin—
FCF Yield—
Net Debt-1.72M USD
Net Debt/EBITDA0.16
Balance Sheet
Debt/Equity0.16
Current Ratio1.36
Quick Ratio1.19
Book Value/Sh0.8150 USD
Cash/Share0.6890 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float4.39M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta-1.19
S&P 52W Chg27.94%
Avg Vol (30d)250
Avg Vol (10d)—
Technical Indicators
RSI (14)52.0
MACD-0.0089
MACD Signal-0.0048
MACD Hist.-0.0041
BB Upper0.3466 USD
BB Middle0.2850 USD
BB Lower0.2234 USD
BB Width43.24%
ATR (14)0.0259 USD
Vol Ratio (20d)0.00x